DOI:

Detection of a necrotic core-rich, highly deformable plaque in an angiographically non-diseased proximal LAD

Gastón A. Rodriguez-Granillo, MD; Raquel del Valle, MD; Jurgen Ligthart, BSc; Patrick W. Serruys*, MD, PhD

Thin-cap fibro atheroma (TCFA) lesions, the most prevalent precursor of plaque rupture, are composed of a lipid-rich necrotic core, a thin-fibrous cap with macrophage and lymphocyte infiltration, decreased smooth muscle cell content and expansive remodeling. Virtual Histology™ uses spectral analysis of intravascular ultrasound (IVUS) radiofrequency data to construct tissue maps that classify plaque into four major components; calcified, fibrous, fibrolipidic and necrotic core regions that are labeled white, green, greenish-yellow and red respectively. Palpography™ evaluates in vivo the mechanical properties of plaque tissue. The local strain is calculated from the radiofrequency traces using cross-correlation analysis and displayed, colour coded, from blue (for 0% strain) through yellow (for 2% strain) via red (Figure 1).

At a defined pressure, soft tissue (lipid-rich) components will deform more than hard (fibrous-calcified) components. Both techniques have been previously validated1,2.

Figure 1a shows an angiographically non-diseased proximal left anterior descending (LAD) artery. IVUS longitudinal reconstruction (Figure 1b) shows diffuse LAD disease. An eccentric mixed plaque that did not compromise the lumen was detected in the proximal LAD (Figure 1c). This segment was further analyzed with Palpography (20 MHz Eagle Eye, Volcano Therapeutics) and Virtual Histology™ (30 MHz Ultracross, Boston Scientific Corp) (Figures 1d and 1e). Despite its innocuous appearance on gray-scale IVUS, highly deformable shoulders with an underlying necrotic core-rich substrate were detected with the aid of strain and compositional imaging.

Although compatible with the presence of a vulnerable plaque, the prognostic value of these findings is currently unknown and needs to be established in large prospective randomized trials. Thus, the patient was discharged on intensive systemic therapy including lipid-lowering agents.

Figure 1. LAD= left anterior descending coronary artery. LCx= Left circumflex coronary artery. LMCA= Left main coronary artery. * Pericardium.

Volume 1 Number 3
Nov 20, 2005
Volume 1 Number 3
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00453 Jul 6, 2026
AnchorMan versus Watchman 2.5: a randomised comparison in left atrial appendage closure
Garot P and Nielsen-Kudsk J
free

Editorial

10.4244/EIJ-E-26-00011 Jul 6, 2026
Comparing transcatheter aortic valves: time to look beyond simplistic categorisations
Blackman D and Maznyczka A
free

Original Research

10.4244/EIJ-D-26-00158 Jul 6, 2026
Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trial
Fontana G et al

Research Correspondence

10.4244/EIJ-D-26-00315 Jul 6, 2026
Validation of the VARC-HBR consensus for defining high bleeding risk in TAVI
Singh M et al

Research Correspondence

10.4244/EIJ-D-26-00271 Jul 6, 2026
Outcomes of percutaneous mechanical aspiration in left-sided infective endocarditis
Lugo-Fagundo NS et al

Flashlight

10.4244/EIJ-D-26-00128 Jul 6, 2026
Concomitant transfemoral aortic and mitral valve replacement
Lianos I et al
Trending articles
335.05

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
48.6

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
45.5

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
32.65

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved